Aptose Biosciences Inc. (APTOF)
OTCMKTS
· Delayed Price · Currency is USD
1.700
-0.080 (-4.49%)
May 14, 2025, 4:00 PM EDT
Aptose Biosciences Employees
Aptose Biosciences had 13 employees as of December 31, 2024. The number of employees decreased by 23 or -63.89% compared to the previous year.
Employees
13
Change (1Y)
-23
Growth (1Y)
-63.89%
Revenue / Employee
n/a
Profits / Employee
-$1,641,000
Market Cap
3.61M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Tian'an Technology Group | 8 |
CytoDyn | 9 |
Glass House Brands | 374 |
Elite Pharmaceuticals | 64 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Aptose Biosciences News
- 13 hours ago - Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - GlobeNewsWire
- 21 days ago - Aptose Announces Auditor Not Standing for Re-Appointment - GlobeNewsWire
- 21 days ago - Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference - GlobeNewsWire
- 6 weeks ago - Aptose Reports Year End 2024 Results and Corporate Highlights - GlobeNewsWire
- 2 months ago - Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance - GlobeNewsWire
- 2 months ago - Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday? - Benzinga
- 2 months ago - Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort - GlobeNewsWire
- 3 months ago - Aptose Announces Reverse Share Split - GlobeNewsWire